IP Library Granted Patent US 8,961,385
Granted Patent B2
US 8,961,385 · App. 13/080,450 · Granted Feb 24, 2015

Devices and method for treatment of degenerative joint diseases with electromagnetic fields

Inventors: Arthur A. Pilla (Oakland, NJ); Andre′ A. DiMino (Woodcliff Lake, NJ); Matthew E. Drummer (Fort Lee, NJ)
Assignee: Ivivi Health Sciences, LLC
A61N1/40A61N2/02A61N2/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,961,385
App. No.
13/080,450
Granted
Feb 24, 2015
Kind
B2
Abstract

Described herein are devices and methods for treating degenerative joint diseases with electromagnetic fields using one or more waveforms that are configured to modulate Ca 2+ binding to calmodulin and thereby modulate calmodulin-dependent nitric oxide signaling within joint and other affected tissue for the purpose of reducing pain and inflammation, as well as enhancing the healing and regeneration of such tissue.

Claims (35)

1. A method of treating degenerative joint disease comprising:

positioning a flexible coil wire applicator of a lightweight wearable or stationary pulsed EMF therapy device adjacent to a joint or tissue to be treated;

applying a treatment regime from the therapy device, wherein the treatment regime comprises bursts of electromagnetic signals having a peak amplitude of less than about 200 milliGauss, wherein the bursts have a duration of between about 0.5 msec and about 50 msec, further wherein the bursts are repeated at an interburst interval of between about 2 seconds and 0.1 second for a treatment on-time, followed by a treatment off-time that is greater than the treatment on-time.

2. The method of claim 1 , wherein the treatment regime is configured according to a mathematical model.

3. The method of claim 2 , wherein the mathematical model is one of a signal to noise ratio (SNR) or power signal to noise ratio (PSNR) in respect to calcium binding to calmodulin, and in further respect to calmodulin-dependent NO signaling.

4. The method of claim 2 , wherein the mathematical model is one of a signal to noise ratio (SNR) or power signal to noise ratio (PSNR) in respect to the asymmetrical kinetics of ion binding to intracellular buffers to increase the rate of calcium binding in further respect to calmodulin-dependent signaling.

5. The method of claim 1 , wherein the treatment regime is configured to incorporate asymmetrical kinetics of ion binding to intracellular buffers to increase the rate of ion binding and enhance a biochemical signaling pathway employed for growth, repair or maintenance.

6. The method of claim 5 , wherein the treatment regime is configured to accelerate Ca 2+ binding to intracellular calcium buffers, such as CaM.

7. The method of claim 1 , wherein the treatment regime is configured to modulate CaM-dependent signaling for cytokine and growth factor production in vivo.

8. The method of claim 1 , wherein the treatment regime is configured to modulate CaM-dependent NO signaling.

9. The method of claim 1 for the treatment of osteoarthritis.

10. The method of claim 1 for the treatment of rheumatoid arthritis.

11. The method of claim 1 for the treatment of spondyloarthritis.

12. The method of claim 1 for the treatment of arthritis.

13. The method of claim 1 , wherein the treatment on-time is between about 1minute and about 60 minutes.

14. The method of claim 1 , wherein the treatment on-time is approximately 15minutes.

15. The method of claim 1 , wherein the treatment on-time is approximately 5minutes.

16. The method of claim 1 , wherein the treatment off-time is between about 15minutes and about 23 hours.

17. The method of claim 1 , wherein the treatment off-time is approximately 11hours.

18. The method of claim 1 , wherein the interburst interval is approximately 1second.

19. The method of claim 1 , wherein the interburst interval is approximately 0.5second.

20. The method of claim 1 , wherein the bursts have a duration of approximately 7msec.

21. The method of claim 1 , wherein the bursts have a duration of approximately 2msec.

22. The method of claim 1 , wherein the electromagnetic waves within the burst have a carrier frequency of about 6.8 MHz.

23. The method of claim 1 , wherein the electromagnetic waves within the burst have a carrier frequency of about 27.12 MHz.

24. The method of claim 1 , wherein the pulse of electromagnetic waves within the burst have a duration of about 0.5 μsec.

25. A method of treating degenerative joint disease comprising:

positioning a flexible coil wire applicator of a lightweight, wearable battery-operated EMF therapy device adjacent to a joint or tissue to be treated;

treating the joint or tissue by applying bursts of electromagnetic waves having a peak amplitude of less than about 200 milliGauss from the therapy device, wherein the bursts have a duration of between about 0.5 msec and about 50msec, further wherein the bursts are repeated at an interburst interval of between about 10 seconds and 0.1 second for a treatment on-time of between about 5minutes and 30 minutes, followed by a treatment off-time that is greater than about 30 minutes.

26. The method of claim 25 , wherein treating the joint or tissue comprises applying bursts of 6.8 MHz sinusoidal electromagnetic waves having a peak amplitude of about 50milliGauss, wherein the duration of the burst is about 7 msec, and bursts repeat approximately every second.

27. A method of treating degenerative joint disease comprising:

applying a coil applicator of a lightweight wearable or stationary pulsed EMF therapy device adjacent to a joint or tissue to be treated;

applying a treatment regime from the therapy device, wherein the treatment regime comprises bursts of electromagnetic waves having a peak amplitude of less than about 200 milliGauss, wherein the bursts have a duration of between about 0.5msec and about 50 msec, further wherein the bursts are repeated at an interburst interval of between about 2 seconds and 0.1 second for a treatment on-time, followed by a treatment off-time that is greater than the treatment on-time.

28. The method of claim 27 , wherein applying the coil applicator comprises applying a brace or garment incorporating the applicator.

29. The method of claim 27 , wherein the coil applicator is applied in conjunction with pharmacological agents such as glucosamine.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2024
From: ENDONOVO THERAPEUTICS, INC.
To: SOFPULSE, INC.
Reel/Frame 067933/0673 →
LICENSE Recorded Sep 24, 2019
From: RIO GRANDE NEUROSCIENCES, INC., ASSIGNOR TO ENDONOVO THERAPEUTICS INC.
To: AAH HOLDINGS LLC
Reel/Frame 050475/0809 →
SECURITY AGREEMENT Recorded Feb 1, 2018
From: ENDONOVO THERAPEUTICS, INC.
To: STEVEN M. GLUCKSTERN
Reel/Frame 045221/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2018
From: RIO GRANDE NEUROSCIENCES, INC.
To: ENDONOVO THERAPEUTICS INC.
Reel/Frame 044644/0182 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2016
From: IVIVI HEALTH SCIENCES, LLC
To: RIO GRANDE NEUROSCIENCES, INC.
Reel/Frame 037445/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2015
From: IVIVI HEALTH SCIENCES, LLC
To: RIO GRANDE NEUROSCIENCES, INC.
Reel/Frame 037394/0244 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2011
From: PILLA, ARTHUR A.; DIMINO, ANDRE' A.; DRUMMER, MATTHEW E.
To: IVIVI HEALTH SCIENCES, LLC
Reel/Frame 026941/0230 →
Continuity (7)
Continuation In Part 12819956 · Jun 21, 2010
Continuation In Part 12772002 · Apr 30, 2010
Continuation 11003108 · Dec 3, 2004
Provisional Application 61321044 · Apr 5, 2010
Provisional Application 61326582 · Apr 21, 2010
Provisional Application 60527327 · Dec 5, 2003
Related Publication 20110207989A1 · Aug 25, 2011